A proof-of-concept study of a a third generation antisence platform, NLRP3 (NOD-like receptor family, pyrin domain containing protein 3) and DUX4 (Double Homeobox 4)
Latest Information Update: 13 Feb 2023
At a glance
- Drugs Tilsotolimod (Primary)
- Indications Facioscapulohumeral muscular dystrophy; Interstitial cystitis; Lupus nephritis; Uveitis
- Focus Adverse reactions; Proof of concept
- 17 Jan 2023 According to an Aceragen media release, Idera Pharmaceuticals has changed its name to Aceragen.
- 17 Aug 2016 New trial record
- 02 Aug 2016 According to an Idera Pharmaceuticals media release this study is expected to initiate in 2017.